Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Melatonin and Diabetic Nephropathy: From Mechanistic Pathways to Translational Opportunities in Clinical Management.

INTRODUCTION/OBJECTIVE Diabetic Nephropathy (DN) remains a leading cause of end-stage renal disease worldwide, characterized by a complex interplay of oxidative stress, chronic inflammation, and circadian rhythm disruption. Despite standard-of-care treatments like RAS inhibitors and newer agents like SGLT2 inhibitors a...

Mohammad Saleh Chapani, Kosar Ostadmohammadi, Mohammad Moulaei-Arani et al. · 0 citations
Oct 2026

Combination of Empagliflozin and Resveratrol Mitigates Hepatic Steatosis via Attenuation of Inflammation and Promotion of Adipose Tissue Browning in High‐Fat Diet‐Fed C57BL/6J Mice

Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a major hepatic complication of obesity with a complex pathogenesis. This study aims to investigate the combined effects of empagliflozin (EMPA) and resveratrol (RSV) treatment on obesity‐associated MASLD in a high‐fat diet (HFD)‐fed mouse model. C57BL...

A. Soleimani, Masoume Aliabadi, Jamal Amri et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.